Use of biomarkers in sepsis: Many questions, few answers

Revista Brasileira de Terapia Intensiva

Volumn 25, Issue 1, 2013, Pages 1-2

  Póvoa, Pedro ^a,b   Salluh, Jorge Ibrain Figueira ^c,d  

^a HOSPITAL DE SÃO FRANCISCO XAVIER   (Portugal)

^b NOVA MEDICAL SCHOOL   (Portugal)

^c D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

HUMAN; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; SEPSIS;

BIOLOGICAL MARKERS; HUMANS; PROGNOSIS; SEPSIS;

EID: 84876481143     PISSN: 0103507X     EISSN: 19824335     Source Type: Journal    
DOI: 10.1590/S0103-507X2013000100001     Document Type: Editorial

References (16)

1. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15.
2. Póvoa P. Serum markers in community-Acquired pneumonia and ventilatorassociated pneumonia. Curr Opin Infect Dis. 2008;21(2):157-62. Review. (Pubitemid 351641519)
3. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov. 2003;2(5):391-405. (Pubitemid 37361709)
4. Ospina-Tascón GA, Büchele GL, Vincent JL. Multicenter, randomized, controlled trials evaluating mortality in intensive care: doomed to fail? Crit Care Med. 2008;36(4):1311-22. (Pubitemid 351482683)
5. Salluh JI, Póvoa P. Biomarkers as end points in clinical trials of severe sepsis: a garden of forking paths. Crit Care Med. 2010;38(8):1749-51.
6. Marshall JC, Vincent JL, Fink MP, Cook DJ, Rubenfeld G, Foster D, et al. Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med. 2003;31(5):1560-7. (Pubitemid 36583875)
7. Institute of Medicine of the National Academies. Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington: The National Academies Press; 2010.
8. Orati JA, Almeida P, Santos V, Ciorla G, Lobo SM. Dosagens séricas de proteína C-reativa na fase inicial da sepse abdominal e pulmonar. Rev Bras Ter Intensiva. 2013;25(1):6-11.
9. Rabello LS, Pitrowsky MT, Soares M, Póvoa P, Salluh JI. Novos marcadores biológicos na pneumonia comunitária grave. Rev Bras Ter Intensiva. 2011;23(4):499-506.
10. Póvoa P. C-reactive protein: a valuable marker of sepsis. Intensive Care Med. 2002;28(3):235-43. (Pubitemid 34230643)
11. Miyano G, Okazaki T, Kato Y, Marusasa T, Takahashi T, Lane GJ, et al. Open versus laparoscopic treatment for pan-eritonitis secondary to perforated appendicitis in children: a prospective analysis. J Laparoendosc Adv Surg Tech A. 2010;20(7):655-7.
12. Lisboa T, Seligman R, Diaz E, Rodriguez A, Teixeira PJ, Rello J. C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-Associated pneumonia. Crit Care Med. 2008;36(1):166-71.
13. Vandijck DM, Hoste EA, Blot SI, Depuydt PO, Peleman RA, Decruyenaere JM. Dynamics of C-reactive protein and white blood cell count in critically ill patients with nosocomial Gram positive vs. Gram negative bacteremia: a historical cohort study. BMC Infect Dis. 2007;7:106.
14. Póvoa P, Teixeira-Pinto AM, Carneiro AH; Portuguese Community-Acquired Sepsis Study Group SACiUCI. C-reactive protein, an early marker of community-Acquired sepsis resolution: a multi-center prospective observational study. Crit Care. 2011;15(4):R169.
15. Salluh JI, Soares M, Coelho LM, Bozza FA, Verdeal JC, Castro-Faria-Neto HC, et al. Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-Acquired pneumonia: a cohort study. J Crit Care. 2011;26(2):193-200.
16. Póvoa P, Souza-Dantas VC, Soares M, Salluh JF. C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia. Crit Care. 2011;15(3):R129.